News
BerGenBio completes recruitment into second stage of Phase II trial with selective AXL inhibitor bemcentinib in combination with KEYTRUDA® in patients with advanced NSCLC
May 8, 2019
Phase II, Simon two-stage trial evaluating bemcentinib and KEYTRUDA in previously treated NSCLC post chemotherapy…
Read More
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2019
May 8, 2019
Advanced leukaemia (AML/MDS): Phase II trial fully recruited and combination trial with low-intensity chemotherapy meets…
Read More
BERGENBIO ASA: INVITATION TO FIRST QUARTER PRESENTATION AND WEBCAST
April 24, 2019
Bergen, Norway, 24 April 2019 – BerGenBio ASA (OSE:BGBIO), will announce its results for the…
Read More
BerGenBio to present NSCLC and AML clinical data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019
April 23, 2019
Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDAAccepted…
Read More
BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference
April 9, 2019
Bergen, Norway, April 09 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing…
Read More
BerGenBio extends Phase II trial with bemcentinib and KEYTRUDA® in NSCLC to include patients with disease progression on immune checkpoint inhibitor therapy
April 2, 2019
Bergen, Norway, 2 April 2019 – BerGenBio ASA (OSE: BGBIO) announces that the first patient…
Read More
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159